Association between Overexpression of Her-2 and Other Clinicopathologic Prognostic Factors in Breast Cancer in Morocco


Background: Breast cancer is the leading cancer among women. The management depends largely on the knowledge of prognostic factors. The aim of our study is to evaluate the overexpression of Her-2/neu in patients with invasive breast carcinoma in Morocco, and to study the association between this overexpression and otherprognostic factors of breast cancer, such as age, tumor size, tumor grade, hormone receptors, vascular space invasion and lymph node status. Methods: This is a transversal study in which we included patients with invasive breast carcinomas treated at University Hospital Ibn Rochd of Casablanca in radiotherapy-oncology departement between January 2008 and December 2010, having had surgery first. Univariate analysis (Chi 2 test and Student’s test) and multivariate (logistic regression) were performed to study this association. Results: The overexpression of Her-2/neu was found in 29.2% of cases. In univariate analysis, Her-2 positive status was significantly correlated with high-grade tumors and large, to a lymph node, vascular space invasion and negative ER/PR. Age alone does not appear as a factor associated with positive Her-2/neu status. In multivariate analysis, the overexpression of Her 2 was significantly associated only with vascular space invasion, high tumor grade and the negativity of estrogen receptors. Conclusion: In our series, only the high grade, the vascular space invasion and the negative hormone receptors are independent factors associated with overexpression of Her 2/neu. Age does not appear as a factor associated with positive Her-2/neu status.

Share and Cite:

Z. Bouchbika, N. Benchakroun, A. Taleb, H. Jouhadi, N. Tawfiq, S. Sahraoui and A. Benider, "Association between Overexpression of Her-2 and Other Clinicopathologic Prognostic Factors in Breast Cancer in Morocco," Journal of Cancer Therapy, Vol. 3 No. 5A, 2012, pp. 787-792. doi: 10.4236/jct.2012.325099.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] I. B. Ghorbela, S. C. Kanouna, A D. Kallela, A. B. Belaida, F. Azourya, S. Heymanna, et al., “Cancer du Sein Sans Atteinte Ganglionnaire Axillaire,” Cancer/Radiothérapie, Vol. 14, Suppl. 1, 2010, pp. S127-S135.
[2] B. Trétarre, A. V. Guizard and D. Fontaine, “Cancer du Sein Chez la Femme: Incidence et Mortalité, France 2000,” BEH, Vol. 44, 2004, pp. 209-210.
[3] T. Akiyama, C. Sudo, H. Ogawara, et al., “The Product of the Human c-erbB-2 Gene: A 185-Kilodalton Glycoprotein with Tyrosine Kinase Activity,” Science, Vol. 232, No. 4758, 1986, pp. 1644-1646. doi:10.1126/science.3012781
[4] D. J. Slamon, W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, et al., “Studies of the HER-2/Neu Proto-Oncogene in Human Breast and Ovarian Cancer,” Science, Vol. 244, No. 4905, 1989, pp. 707-712. doi:10.1126/science.2470152
[5] G. Pauletti, W. Godolphin, M. F. Press and D. J. Slamon, “Detection and Quantitation of HER-2/Neu Gene Amplification in Human Breast Cancer Archival Material Using Fluorescence in Situ Hybridization,” Oncogene, Vol. 13, No. 1, 1996, pp. 63-72.
[6] T. Rajkumar and W. J. Gullick, “The Type I Growth Factor Receptors in Human Breast Cancer,” Breast Cancer Research and Treatment, Vol. 29, No. 1, 1994, pp. 3-9. doi:10.1007/BF00666177
[7] C. R. De Potter and A. M. Schelfhout, “The Neu-Protein and Breast Cancer,” Virchows Arch, Vol. 426, No. 2, 1995, pp. 107-115.
[8] G. Pauletti, S. Dandekar, H. Rong, L. Ramos, H. Peng, R. Seshadri and D. J. Slamon, “Assessment of Methods for Tissue-Based Detection of the HER-2/Neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence in Situ Hybridization and Immunohistochemistry,” Journal of Clinical Oncology, Vol. 18, No. 21, 2000, pp. 3651-3664.
[9] D. Varshney, Y. Y. Zhou, S. A. Geller and R. Alsabeh, “Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest and PathVysion FISH Assay,” American Journal of Clinical Pathology, Vol. 121, No. 1, 2004, pp. 70-77. doi:10.1309/FUQH92B039025LHG
[10] C. C. Benz, G. K. Scott, J. C. Sarup, et al., “Estrogen-Dependent, Tamoxifen-Resistant Tumorigenic Growth of MCF-7 Cells Transfected with HER2/Neu,” Breast Cancer Research and Treatment, Vol. 24, No. 2, 1993, pp. 85-95. doi:10.1007/BF01961241
[11] D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich and W. L. McGuire, “Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/Neu Oncogene,” Science, Vol. 235, No. 4785, 1987, pp. 177-182. doi:10.1126/science.3798106
[12] B. A. Gusterson, R. D. Gelber, A. Goldhirsch, et al., “Prognostic Importance of c-erbB-2 Expression in Breast Cancer,” Journal of Clinical Oncology, Vol. 10, No. 7, 1992, pp. 1049-1056.
[13] P. Kronqvist, T. Kuopio, M. Nykanen, et al., “Predicting Aggressive Outcome in T1N0M0 Breast Cancer,” British Journal of Cancer, Vol. 91, No. 2, 2004, pp. 277-281.
[14] S. B. Bull, H. Ozcelik, D. Pinnaduwage, et al., “The Combination of p53 Mutation and Neu/erbB-2 Amplification Is Associated with Poor Survival in Nodenegative Breast Cancer,” Journal of Clinical Oncology, Vol. 22, No. 1, 2004, pp. 86-96. doi:10.1200/JCO.2004.09.128
[15] F. Tavassoli and P. Devilee, “World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs,” IARC Press, Lyon, 2003.
[16] E. W. Elston and I. O. Ellis, “Method for Grading Breast Cancer,” Journal of Clinical Pathology, Vol. 46, No. 2, 1993, pp. 189-190.
[17] D. C. Allred, J. M. Harvey, M. Berardo and G. M. Clark, “Prognostic and Predictive Factors in Breast Cancer by Immunohistochemical Analysis,” Modern Pathology, Vol. 11, No. 2, 1998, pp. 155-168.
[18] S. J. Schnitt, “Traditional and Newer Pathologic Factors,” Journal of the National Cancer Institute. Monographs, Vol. 2001, No. 30, 2001, pp. 22-26. doi:10.1093/oxfordjournals.jncimonographs.a003456
[19] D. Cameron and R. Bell, “Optimizing Treatment for Patients with Breast Cancer,” Seminars in Oncology, Vol. 31, No. 10, 2004, pp. 4-5. doi:10.1053/j.seminoncol.2004.07.015
[20] L. Ayadi, A. Khabir, H. Amouri, S. Karray, A. Dammak, M. Guermazi and T. Boudawara, “Correlation of HER-2 Over-Expression with Clinico-Pathological Parameters in Tunisian Breast Carcinoma,” World Journal of Surgical Oncology, Vol. 6, 2008, p. 112. doi:10.1186/1477-7819-6-112
[21] T. El-AHelal, A. Khalifa and A. S. Kamel, “Immunohistochemical Expression of p53 and cerbB2 Proteins in Breast Cancer in Egypt,” Anticancer Research, 20, 3B, 2000, pp. 2145-2150.
[22] S. Taucher, M. Rudas, R. M. Mader, M. Gnant, P. Dubsky, T. Bachleitner, et al., “Do We Need HER-2/Neu Testing for All Patients with Primary Breast Carcinoma?” Cancer, Vol. 98, No. 12, 2003, pp. 2547-2553. doi:10.1002/cncr.11828
[23] S. Eppenberger-Castori, D. H. Moore Jr., A. D. Thor, S. M. Edgerton, W. Kueng, U. Eppenberger and C. C. Benz, “Age-Associated Biomarker Profiles of Human Breast Cancer,” The International Journal of Biochemistry & Cell Biology, Vol. 34, No. 11, 2002, pp. 1318-1330. doi:10.1016/S1357-2725(02)00052-3
[24] N. M. Almasri and M. Al Hamad, “Immunohistochemical Evaluation of Human Epidermal Growth Factor Receptor 2 and Estrogen and Progesterone Receptors in Breast Carcinoma in Jordan,” Breast Cancer Research, Vol. 7, No. 5, 2005, pp. R598-R604. doi:10.1186/bcr1200
[25] H. J. Huang, P. Neven, M. Drijkoningen, R. Paridaens, H. Wildiers, E. Van Limbergen, et al., “Hormone Receptors Do Not Predict the HER2/Neu Status in All Age Groups of Women with an Operable Breast Cancer,” Annals of Oncology, Vol. 16, No. 11, 2005, pp. 1755-1761. doi:10.1093/annonc/mdi364
[26] B. K. Seo, E. D. Pisano, C M. Kusimak, M. Koomen, D. Pavic, Y. Lee, E. B. Cole and J. Y. Lee, “Correlation of HER-2/Neu Overexpression with Mammography and Age Distribution in Primary Breast Carcinomas,” Academic Radiology, Vol. 13, No. 10, 2006, pp. 1211-1218. doi:10.1016/j.acra.2006.06.015
[27] J. M. Bhatavdekar, D. D. Patel, N. G. Shah, H. H. Vora, T. P. Suthar, P. R. Chikhlikar, et al., “Prognostic Significance of Immunohistochemically Localized Biomarkers in Stage II and Stage III Breast Cancer: A Multivariate Analysis,” Annals of Surgical Oncology, Vol. 7, No. 4, 2000, pp. 305-311. doi:10.1007/s10434-000-0305-5
[28] T. Ivkovic-Kapicl, S. Knezevic-Usaj, D. Djilas-Ivanovic and M. Panjkovic, “Correlation of HER-2/Neu Protein Overexpression with Other Prognostic and Predictive Factors in Invasive Ductal Breast Cancer,” Anticancer Research, Vol. 21, No. 4, 2007, pp. 673-678
[29] R. Prati, S. K. Apple, J. He, J. A. Gornbei and H. R. Chanh, “Histopathologic Characteristics Predicting HER-2/Neu Amplification in Breast Cancer,” Breast Journal, Vol. 11, No. 6, 2005, pp. 433-439. doi:10.1111/j.1075-122X.2005.00125.x
[30] H. J. Huang, P. Neven, M. Drijkoningen, R. Paridaens, H. Wildiers, E. Van Limberger, P. Berteloot, F. Amant, I. Vergote and M. R. Christiaens, “Association between Tumour Characteristics and HER-2/Neu by Immunohistochemistry in 1362 Women with Primary Operable Breast Cancer,” Journal of Clinical Pathology, Vol. 58, No. 6, 2005, pp. 611-616. doi:10.1136/jcp.2004.022772
[31] S. Paik, J. Brayant, C. Park, B. Fisher, E. Tan-Chiu, D. Hyams, et al., “ErbB-2 and Response to Doxorubicin in Patients with Axillary Lymph-Node Positive, Hormone Receptor-Negative Breast Cancer,” Journal of the National Cancer Institute, Vol. 90, No. 18, 1998, pp. 1361-1370. doi:10.1093/jnci/90.18.1361
[32] R. Ariga, A. Zarif, J. Korasick, V. Reddy, K. Siziopikou and P. Gattuso, “Correlation of Her 2/Neu Gene Amplification with Other Prognostic and Predictive Factors in Female Breast Carcinoma,” Breast Journal, Vol. 11, No. 4, 2005, pp. 278-280. doi:10.1111/j.1075-122x.2005.21463.x
[33] E. R. Hoff, R. R. Tubbs, J. L. Myles and G. W. Procop, “HER-2/Neu Amplification in Breast Cancer. Stratification by Tumor Type and Grade,” Am Journal of Clinical Pathology, Vol. 117, No. 6, 2002, pp. 916-921. doi:10.1309/4NTU-N6K4-F8JF-EWRX
[34] I. L. Andrulis, S. B. Bull, M. E. Blackstein, D. Sutherland, C. Mak, S. Sidlofsky, et al., Toronto Breast Cancer Study Group, “Neu/erbB-2 Amplification Identifies a Poor-Prognosis Group of Women with Node-Negative Breast Cancer,” Journal of Clinical Oncology, Vol. 16, No. 4, 1998, pp. 1340-1349.
[35] A. Traina, B. Agostara, L. Marasà, M. Calabrò, M. Zarcone and G. Carruba, “HER2/Neu Expression in Relation to Clinicopathologic Features of Breast Cancer Patients,” Annals of the New York Academy of Sciences, Vol. 1089, 2006, pp. 159-167. doi:10.1196/annals.1386.029
[36] A Harlozinska, J. K. Bar, R. Wenderski and M. Bebenek, Association with Tumor Phenotypes, “Relationship between c-erbB-2 Oncoprotein, Epidermal Growth Factor Receptor, and Estrogen Receptor Expression in Patients with Ductal Breast Carcinoma,” In Vivo, Vol. 10, No. 2, 1996, pp. 217-222.
[37] S. A. Aziz, S. Pervez, S. Khan, N. Kayani, S. I. Azam and M. H. Rahbar, “Significance of Immunohistochemical Pattern for Prognosis in Human Breast Cancer,” Pathology & Oncology Research, Vol. 7, No. 3, 2001, pp. 190-196. doi:10.1007/BF03032348
[38] S. Kariya, Y. Ogawa, A. Nishioka, T. Moriki, T. Ohnishi, S. Ito, Y. Murata and S. Yoshida, “Relationship between Hormonal Receptors, HER-2, p53 Protein, bcl-2, and MIB-1 Status and the Antitumor Effects Of Neoadjuvant Anthracycline-Based Chemotherapy in Invasive Breast Cancer Patients,” Radiation Medicine, Vol. 23, No. 3, 2005, pp. 189-194.
[39] A. E. Pinto, S. Andre, T. Pareira, S. Nobrega and J. Soares, “C-erbB-2 Oncoprotein Overexpression Identifies a Subgroup of Estrogen Receptor Positive (ER+) Breast Cancer Patients with Poor Prognosis,” Annals of Oncology, Vol. 12, No. 4, 2001, pp. 525-33. doi:10.1023/A:1011163211802
[40] S. Kaptain, L. K. Tan and B. Chen, “Her-2/Neu and Breast Cancer,” Diagnostic Molecular Pathology, Vol. 10, 3, 2001, pp. 139-152. doi:10.1097/00019606-200109000-00001
[41] S. Selvarajan, K. Y. Wong, K. S. Khoo, B. H. Bay and P. H. Tan, “Overexpression of c-erbB2 Correlates with Nu- clear Morphometry and Prognosis in Breast Carcinoma in Asian women,” Pathology, Vol. 38, No. 6, 2006, pp. 528-533. doi:10.1080/00313020601024060
[42] S. Taucher, M. Rudas, R. M. Mader, M. Gnant, P. Dubsky, T. Bachleitner and S. Roka, “Do We Need HER-2/Neu Testing for All Patients with Primary Breast Carcinoma?” Cancer, Vol. 98, No. 12, 2003, pp. 2547-2553. doi:10.1002/cncr.11828

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.